<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498081</url>
  </required_header>
  <id_info>
    <org_study_id>D3060C00003</org_study_id>
    <secondary_id>EudraCT number: 2011-004641-41</secondary_id>
    <nct_id>NCT01498081</nct_id>
  </id_info>
  <brief_title>A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD Patients</brief_title>
  <official_title>A Randomised, Double-blind, Placebo and Active Controlled, Multi-centre, 6 Way Cross-over, Single-dose Phase IIa Study to Investigate the Local and Systemic Effects of 3 Different Doses of Inhaled AZD2115 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study in COPD patients will investigate the bronchodilatory effect of AZD2115. AZD2115
      will be tested versus placebo and active comparators. The safety and tolerability of AZD2115
      including investigations of clinically relevant systemically mediated effects will also be
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, placebo and active controlled, multi-centre, 6 way cross-over,
      single-dose Phase IIa study to investigate the local and systemic effects of 3 different
      doses of inhaled AZD2115 in patients with chronic obstructive pulmonary disease (COPD)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Forced Expiratory Volume in 1 second (FEV1) defined as the maximum FEV1 from the spirometry assessments</measure>
    <time_frame>During the first 24 hours following administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1defined as the average FEV1 from the spirometry assessments</measure>
    <time_frame>During 22 to 26 hours following administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1</measure>
    <time_frame>FEV1 0-24h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak, average and trough Forced Vital Capacity (FVC)</measure>
    <time_frame>FVC peak and average 0-24h post-dose and trough 22-26h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic effect by assessment of blood pressure (BP)</measure>
    <time_frame>Peak and average 0-4 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic effect by assessment of heart rate (HR) and QT interval corrected for heart rate using Fridericia's formula (QTcF)</measure>
    <time_frame>Peak and average 0-4 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic effect by assessment of Potassium and Glucose</measure>
    <time_frame>Peak and average 0-4 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of 3 different single doses of AZD2115</measure>
    <time_frame>At screening, during 0-26 h post-dose and at follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of AZD2115 after 3 different single doses measured as area under the curve over the time (AUC) and maximum concentration (Cmax), and time to maximum concentration (tmax)</measure>
    <time_frame>0-24h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Single dose of AZD2115 25 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of AZD2115 80 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of AZD2115 240 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single doses of placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of indacaterol 150 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose of indacaterol 150 µg + tiotropium 18 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2115</intervention_name>
    <description>AZD2115 administered via inhalation</description>
    <arm_group_label>Single dose of AZD2115 25 µg</arm_group_label>
    <arm_group_label>Single dose of AZD2115 80 µg</arm_group_label>
    <arm_group_label>Single dose of AZD2115 240 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered via inhalation</description>
    <arm_group_label>Single doses of placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>Indacaterol administered via inhalation</description>
    <arm_group_label>Single dose of indacaterol 150 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol + Tiotropium</intervention_name>
    <description>Indacaterol + Tiotropium administered inhalation</description>
    <arm_group_label>Single dose of indacaterol 150 µg + tiotropium 18 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Male or female of non-childbearing potential (post-menopausal or surgically
             sterilised), age ≥40 years at Visit 1

          -  Clinical diagnosis of COPD for more than 1 year at Visit 1, according to GOLD
             guidelines

          -  Post-bronchodilator FEV1 ≥ 40 to &lt; 80% of the predicted normal value and
             post-bronchodilator FEV1/FVC &lt; 70%

          -  Reversible airway obstruction

        Exclusion Criteria:

          -  Significant disease or disorder which, in the opinion of the Investigator, may either
             put the patient at risk because of participation in the study, or influence the result
             of the study, or the patient's ability to participate in the study.

          -  An exacerbation of COPD within 6 weeks prior to Visit 1

          -  Treatment with systemic glucocorticosteroids with 6 weeks of Visit 2.

          -  Recent or ongoing respiratory tract infection during enrolment period.

          -  Need for long-term oxygen therapy and/or saturation O2 &lt; 92%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin Jorup, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Molndal, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leczna</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

